title: [Alendronate-induced hepatocellular lesion].
abstract: Bisphosphonates are widely used in the treatment of metabolic bone disease. Bisphosphonate-induced hepatotoxicity is extremely infrequent. We present the case of a 76-year-old female patient with osteoporosis who was prescribed alendronate. A routine laboratory investigation carried out three months later revealed markedly elevated transaminase concentrations. Six weeks after withdrawal of treatment, laboratory parameters had returned to normal levels. We analyze this adverse reaction to alendronate as well as its possible pathogenic mechanisms.
authors: Unidad de Digestivo. Hospital Virgen de la Concha. Zamora.
authors: C
authors: C
authors: de La Serna Higuera
authors: A
authors: A
authors: Pérez Villoria
authors: S
authors: S
authors: Rodríguez Gómez
authors: J
authors: J
authors: Martínez Moreno
authors: A
authors: A
authors: Betancourt González
authors: M
authors: M
authors: Martín Arribas
mesh_terms: D000368:Aged; D019386:Alendronate / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy
chemical_list: D019386:Alendronate